Aberrant methylation of breast and ovarian cancer susceptibility gene 1 in chemosensitive human ovarian cancer cells does not involve the phosphatidylinositol 3′-kinase-Akt pathway

Cancer Science

Volumn 101, Issue 7, 2010, Pages 1618-1623

  Wang, Yan Qiu ^a   Zhang, Jia Rong ^a   Li, Shuang Di ^a   He, Yin Yan ^a   Yang, Yi Xia ^a   Liu, Xue Lian ^a   Wan, Xiao Ping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; BRCA1 PROTEIN; CISPLATIN; DNA; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CHEMOSENSITIVITY; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA EXTRACTION; DNA METHYLATION; GENE EXPRESSION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; OVARY CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR SUPPRESSOR PROTEINS;

EID: 77954707617     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01568.x     Document Type: Article

References (33)

1. Ozols RF, Bookman MA, Connolly DC. Focus on epithelial ovarian cancer. Cancer Cell 2004, 5:19-24.
2. Horváth V, Blanárová O, Svihálková-Sindlerová L. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecol Oncol 2006, 102:32-40.
3. Li M, Balch C, Montgomery JS. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2009, 2:34.
4. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4:143-53.
5. Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003, 22:7512-23.
6. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007, 128:683-92.
7. Konstantinopoulos PA, Fountzilas E, Pillay K. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics 2008, 1:59.
8. James G, Herman MD, Stephen B, Baylin MD. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042-54.
9. Lee MN, Tseng RC, Hsu HS. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin Cancer Res 2007, 13:832-8.
10. Billack B, Monteiro AN. BRCA1 in breast and ovarian cancer predisposition. Cancer Lett 2005, 227:1-7.
11. Taniguchi T, Tischkowitz M, Ameziane N. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors[J]. Nat Med 2003, 9(5):568-74.
12. Fan W, Jin S, Tong T. BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs[J]. J Biol Chem 2002, 277(10):8061-7.
13. Zhang J, Feng Z, Kim S. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair[J]. Mol Cell Biol 2004, 24(2):708-18.
14. Kissel CK, Schadendorf D, Röckmann H. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific. Melanoma Res 2006, 16(6):527-35.
15. Zhang X-Y, Zhang H-Y, Zhang P-N, Lu X, Hong S. Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer. Eur J Obstet Gynecol Reprod Biol 2008, 139:237-44.
16. Zhang HY, Zhang PN, Sun H. Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur J Obstet Gynecol Reprod Biol 2009, 146:81-6.
17. Jordan NJ, Gee JMW, Barrow D, Wakeling AE, Nicholson RI. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat 2004, 87:167-80.
18. Xiang T, Ohashi A, Huang Y. Negative regulation of AKT activation by BRCA1. Cancer Res 2008, 68:10040-4.
19. Esteller M, Silva JM, Dominguez G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast cancer and ovarian tumors. J Natl Cancer Inst 2000, 92:564-9.
20. Zhong Q, Wen YJ, Yang HS. Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice. Ann Oncol 2008, 19:1584-91.
21. Quinn JE, Carser JE, James CR, Kennedy RD, Harkin DP. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol 2009, 113:134-42.
22. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004, 4:665-76.
23. Rathi A, Virmani AK, Schorge JO. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 2002, 8:3324-31.
24. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006, 8(4):R38.
25. Moynahan ME. The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans. Oncogene 2002, 21:8994-9007.
26. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000, 408:429-32.
27. Chan KY, Ozçelik H, Cheung AN, Ngan HY, Khoo US. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 2002, 62:4151-6.
28. Teodoridis JM, Hall J, Marsh S. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005, 65:8961-7.
29. Catteau A, Morris JR. BRCA1 methylation: a significant role in tumour development? Semin Cancer Biol 2002, 12:359-71.
30. Li M, Balch C, Montgomery JS. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2009, 8:34.
31. Karpinski P, Ramsey D, Grzebieniak Z, Sasiadek MM, Blin N. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer. Mol Cancer Res 2008, 6:585-91.
32. Wu Q, Lothe RA, Ahlquist T. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer 2007, 10:6-45.
33. Wei SH, Chen CM, Strathdee G. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002, 8:2246-52.